1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Appili Therapeutics Inc.
  6. Company
    APLI   CA03783R1073

APPILI THERAPEUTICS INC.

(APLI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is focused on the acquisition and development of medicines targeting infectious disease. The Company also focused on building and advancing a diverse portfolio of anti-infective programs. Its anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. The ATI-2307 is used for the treatment of invasive fungal infections with a near-term focus on those caused by Cryptococcus and Candida. The ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The ATI-1503 is a drug discovery program builds off the molecular structure of negamycin, a naturally occurring compound that can kill Gram-negative bacteria. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole. Metronidazole is a front-line antibiotic for the treatment of anaerobic bacterial and parasitic infections. The Favipiravir is an oral covid-19 antiviral candidate.

Number of employees : 16 people.
Sales per Business
20202021Delta
Novel Drug Development and Clinical Research0.20100%---
CAD in Million
Sales per region
20202021Delta
Canada0.20100%---
CAD in Million
Managers
Name Title Age Since
Armand L. Balboni, Dr. Chief Executive Officer & Director 54 2019
Kenneth G. Howling Chief Financial Officer - 2021
Yoav Golan, Dr. Chief Medical Officer 59 2020
Stéphane Paquette, Dr. Director-Business Development - 2019
Don Cilla, Dr. Chief Development Officer - 2020
Myriam Triest Senior Director-Drug Development - -
Jason McEwan Director-Regulatory Affairs - 2020
Members of the board
Name Title Age Since
Ian C. Mortimer Chairman 45 2020
Theresa Matkovits, Dr. Independent Director 53 2018
Juergen Kurt Froehlich, Dr. Independent Director 65 2020
Rochelle C. Stenzler Independent Director 67 2021
Brian Bloom Director 45 2019
Armand L. Balboni, Dr. Chief Executive Officer & Director 54 2019
Josef Vejvoda Director 56 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 71,266,120 56,186,411 78.8% 0 0.0% 78.8%
Shareholders
NameEquities%
Aipharma Global Holdings LLC 15,079,709 21.2%
Brian Bloom 14,358,611 20.1%
K2 & Associates Investment Management, Inc. 7,321,243 10.3%
Juergen Kurt Froehlich 0 -
Ian C. Mortimer 0 -
Kenneth G. Howling 0 -
Rochelle C. Stenzler 0 -
Josef Vejvoda 0 -
Kimberly Stephens 0 -
Theresa Matkovits 0 -
Company contact information
Appili Therapeutics, Inc.
1344 Summer Street
Suite 21
Halifax, NS B3H 0A8

Phone : +1.902.442.4655
Web : http://www.appilitherapeutics.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Appili Therapeutics Inc.